Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
IL-19 AS A BIOMARKER OF TSLP TREATMENT
Document Type and Number:
WIPO Patent Application WO/2013/063062
Kind Code:
A3
Abstract:
The disclosure relates to the use of IL-19 as a biomarker for treatment using a TSLP antagonist. More specifically, the disclosure provides methods for measuring the IL-19 expression levels in a biomedical sample for monitoring TSLP blockade in a mammalian subject treated with a TSLP antagonist, determining the progression in subjects undergoing treatment with a TSLP antagonist, or selecting subjects having allergic diseases, such as atopic dermatitis and asthma, for treatment using a TSLP antagonist.

Inventors:
BJORCK PIA (US)
Application Number:
PCT/US2012/061614
Publication Date:
August 07, 2014
Filing Date:
October 24, 2012
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MERCK SHARP & DOHME (US)
BJORCK PIA (US)
International Classes:
A61K39/395; C12Q1/68; G01N33/53
Foreign References:
US20100136003A12010-06-03
US20040166521A12004-08-26
US20100098687A12010-04-22
US20090186022A12009-07-23
Other References:
HUANG ET AL.: "Potentiation of IL -19 expression in airway epithelia by IL -17A and IL -4/ IL -13: Important implications in asthma.", J ALLERGY CLIN IMMUNOL., vol. 121, no. 6, 2008, pages 1415 - 1421, XP022760251
NGUYEN ET AL.: "TSLP directly impairs pulmonary Treg function: association with aberrant tolerogenic immunity in asthmatic airway.", ALLERGY ASTHMA CLIN IMMUNOL., vol. 6, no. 1, 2010, pages 1 - 11, XP021079211
BOEHME ET AL.: "A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation.", INT IMMUNOL., vol. 21, no. 1, 2009, pages 81 - 93, XP055150355
See also references of EP 2771687A4
Attorney, Agent or Firm:
MERCK SHARP & DOHME CORP. (Rahway, NJ, US)
Download PDF: